Shots:

• Sage has reported topline data from the P-II (LIGHTWAVE) study assessing the safety & efficacy of dalzanemdor vs PBO for treating patients (n=174) with mild cognitive impairment (MCI) or dementia associated with Alzheimer’s Disease (AD), for 12wks.
• The study found no significant difference on the WAIS-IV Coding Test score at D84 (1EP) and RBANS or MoCA total scores (exploratory endpoints). Safety profile was well-tolerated, with mild to moderate TEAEs
• The company will not continue with the trial. Topline data from its other P-II (DIMENSION) trial of dalzanemdor for cognitive impairment due to Huntington’s disease is anticipated Q4’24

Ref: Sage Therapeutics | Image: Sage Therapeutics

Related News:- Cybrexa Therapeutics Doses the First Patient with CBX-12 Under P-II Study for Treating Ovarian Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com